Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 11/20 | 0.72 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.71 |
| ▸ | DHFR | P00374 | 2/20 | 0.71 |
| ▸ | HNF4A | P41235 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TTR | P02766 | 1/20 | 0.62 |
| ▸ | ALB | P02768 | 1/20 | 0.62 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27630318 | 0.86 | ACMSD (0.71) | ACMSDMCL1DHFRHNF4AALDH1A1 | |
| SCHEMBL14252243 | 0.86 | DCLRE1B (0.67) | ACMSDMCL1DHFRHNF4ADCLRE1B | |
| SCHEMBL411333 | 0.86 | ACMSD (0.65) | ACMSDMCL1DHFRHNF4AKDM4E | |
| SCHEMBL29363677 | 0.84 | DCLRE1B (0.60) | ACMSDMCL1DHFRHNF4ADCLRE1B | |
| SCHEMBL2160051 | 0.84 | DCLRE1B (0.60) | ACMSDMCL1DHFRHNF4ADCLRE1B | |
| SCHEMBL330405 | 0.84 | ACMSD (0.72) | ACMSDMCL1DHFRHNF4AKDM4E | |
| SCHEMBL23143193 | 0.83 | ACMSD (1.00) | ACMSDMCL1DHFRHNF4ALCK | |
| SCHEMBL9273036 | 0.83 | ACMSD (1.00) | ACMSDMCL1DHFRHNF4ALCK | |
| SCHEMBL29759663 | 0.83 | ACMSD (1.00) | ACMSDMCL1DHFRHNF4ALCK | |
| SCHEMBL330602 | 0.83 | ACMSD (1.00) | ACMSDMCL1DHFRHNF4ALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382882-B2 | Anti-virulence compositions and methods | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210308082-A9 | ANTI-VIRULENCE COMPOSITIONS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2021-10-07 | — | — | US | disclosed |
| US-20200237692-A1 | ANTI-VIRULENCE COMPOSITIONS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2020-07-30 | — | — | US | disclosed |
| US-10227282-B2 | Anti-virulence compositions and methods | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20140336258-A1 | ANTI-VIRULENCE COMPOSITIONS AND METHODS | CASE WESTERN RESERVE UNIVERSITY | 2014-11-13 | — | — | US | disclosed |
| US-20140336258-A1 | ANTI-VIRULENCE COMPOSITIONS AND METHODS | CASE WESTERN RESERVE UNIVERSITY | 2014-11-13 | — | — | US | disclosed |
| US-8859626-B2 | Anti-virulence compositions and methods | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859626-B2 | Anti-virulence compositions and methods | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-10-14 | — | — | US | disclosed |
| US-20110218226-A1 | ANTI-VIRULENCE COMPOSITIONS AND METHODS | CASE WESTERN RESERVE UNIVERSITY | 2011-09-08 | — | — | US | disclosed |
| US-20110218226-A1 | ANTI-VIRULENCE COMPOSITIONS AND METHODS | CASE WESTERN RESERVE UNIVERSITY | 2011-09-08 | — | — | US | disclosed |
| CN-1867340-A | Topical use of halosalicylic acid derivatives | AVON PROD INC (US) | 2006-11-22 | — | — | CN | disclosed |
| EP-1694337-A2 | TOPICAL USE OF HALOSALICYLIC ACID DERIVATIVES | AVON PRODUCTS, INC. (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2006-03-30 | — | — | US | disclosed |
| WO-2006004803-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005058230-A2 | TOPICAL USE OF HALOSALICYLIC ACID DERIVATIVES | AVON PRODUCTS, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050136015-A1 | Topical use of halosalicylic acid derivatives | AVON PRODUCTS, INC. | 2005-06-23 | — | — | US | disclosed |
| EP-0017102-A1 | Composition containing a phenyl benzoic acid compound and acetaminophen combination for the treatment of pain and inflammation and process for preparing the same | MERCK & CO. INC. (US) | 1980-10-15 | — | — | EP | disclosed |
| EP-0017169-A1 | Improved anti-inflammatory combinations having reduced ulcerogenicity | MERCK & CO. INC. (US) | 1980-10-15 | — | — | EP | disclosed |
| US-4228161-A | INDOMETHACIN AND A SUBSTITUTED PHENYL BENZOIC ACID | MERCK & CO., INC. (US) | 1980-10-14 | — | — | US | disclosed |
| US-4217340-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 1980-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336258-A1 | ANTI-VIRULENCE COMPOSITIONS AND METHODS | ANTXR2, PURB, CAPG | ACMSD 1128/4885MCL1 2750/4885DHFR 4100/4885 |
| US-20210308082-A9 | ANTI-VIRULENCE COMPOSITIONS AND METHODS | ANTXR2, PURB, CAPG | ACMSD 1128/4885MCL1 2750/4885DHFR 4100/4885 |
| US-20110218226-A1 | ANTI-VIRULENCE COMPOSITIONS AND METHODS | ANTXR2, PURB, CAPG | ACMSD 1128/4885MCL1 2750/4885DHFR 4100/4885 |
| US-20200237692-A1 | ANTI-VIRULENCE COMPOSITIONS AND METHODS | ANTXR2, PURB, CAPG | ACMSD 1128/4885MCL1 2750/4885DHFR 4100/4885 |
| US-20050136015-A1 | Topical use of halosalicylic acid derivatives | NACA, TYR, PRKDC | ACMSD 1718/4885MCL1 729/4885DHFR 2300/4885 |
| US-10227282-B2 | Anti-virulence compositions and methods | ANTXR2, PURB, CAPG | ACMSD 1128/4885MCL1 2750/4885DHFR 4100/4885 |
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | LIPC, PNLIP, GOT2 | ACMSD 3350/4885MCL1 3721/4885DHFR 960/4885 |
| US-11382882-B2 | Anti-virulence compositions and methods | ANTXR2, PURB, CAPG | ACMSD 1128/4885MCL1 2750/4885DHFR 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.